This week's Fierce Biotech is brought to you by Thermo Fisher Scientific.

Trouble viewing? Click here.


 
 
 

It's not uncommon for companies who launch commercial drug products in the pre-filled syringe format to do so after initially using other product formats such as vials for the development and clinical trial phases. Switch-overs need careful and strategic consideration because doing so requires investment in the new format but also offers critical patient benefits and improved stakeholder outcomes.

Download this whitepaper to learn:

  • Critical patient benefits and improved outcomes of prefilled syringes
  • How to select the most appropriate prefilled syringe
  • How to bridge vials with prefilled syringes
 
 
 
 
 
 

Thermo Fisher Scientific, 4815 Emperor Blvd., Durham, NC 27703-8470, USA
+1 866-728-4366 |  +1 919-226-3200 |  Contact Us |  Privacy Policy


Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017